PE-22-28: Uses, Benefits & Research

What is PE-22-28?

PE-22-28 is a synthetic analog of spadin, a peptide derived from the sortilin protein. It was designed to inhibit TREK-1 (TWIK-related potassium channel-1), a two-pore domain potassium channel that has been implicated in depression through genetic studies in mice. PE-22-28 represents a molecular weight of approximately 2,000 Da and has been studied exclusively through intracerebroventricular and intraperitoneal injection in rodent models.

This compound has zero human studies, zero clinical trials, and no development program toward regulatory approval. It exists purely in the academic research space as a pharmacological tool for studying TREK-1 channel biology.

Mechanism of Action

PE-22-28 works through a mechanism entirely distinct from all existing antidepressants:

TREK-1 potassium channel inhibition: TREK-1 is a two-pore domain potassium channel expressed widely in the brain. Knockout mice lacking TREK-1 display an antidepressant-resistant phenotype, suggesting the channel plays a role in mood regulation. PE-22-28 blocks this channel, reducing potassium efflux and altering neuronal excitability.

Downstream effects (all preclinical):

• Hippocampal neurogenesis — new neuron growth in the dentate gyrus (mouse data, Djelloul 2015)
• BDNF upregulation — increased brain-derived neurotrophic factor expression
• Behavioral effects — reduced immobility in forced swim and tail suspension tests (standard rodent depression models)

No human binding assays, no human functional data, and no confirmed mechanism translation have been performed. TREK-1 channel distribution and function may differ between rodents and humans.

Clinical Evidence

Human Studies

None. Zero human studies of any kind — no safety studies, no pharmacokinetic studies, no efficacy trials. Neither PE-22-28 nor its parent compound spadin has been administered to humans in any published study.

Preclinical

• Mazella 2010 (PMID: 20096941): Original discovery of spadin as a TREK-1 inhibitor with antidepressant-like activity in mouse behavioral models (forced swim test, novelty-suppressed feeding).
• Djelloul 2015 (PMID: 26100954): PE-22-28 showed improved stability over spadin, produced antidepressant-like effects in mice, and stimulated hippocampal neurogenesis. CREB pathway activation confirmed.
• Additional structure-activity relationship studies have explored PE-22-28 analogs but remain in basic research.

Drug Interactions & Contraindications

No formal drug interaction studies have been conducted. Theoretical concerns exist for co-administration with SSRIs/SNRIs (unknown mechanism overlap), anticonvulsants (ion channel interactions), and lithium (CNS effects). No contraindications are established because no human exposure data exists. Theoretical concerns include seizure disorders and cardiac arrhythmias due to TREK channel expression in brain and heart tissue.

Safety & Side Effects

No human safety data exists. The only safety information comes from basic animal toxicology that has not been published in detail. Theoretical safety concerns include unpredictable CNS effects from brain potassium channel modulation, potential seizure risk, and cardiac effects from TREK channel blockade in heart tissue.

Honest Bottom Line

PE-22-28 represents the earliest possible stage of drug development — pure preclinical research with zero human exposure. The TREK-1 mechanism is genuinely novel and scientifically interesting because it offers a truly different approach to depression, distinct from the serotonin/norepinephrine modulation used by every approved antidepressant. However, novelty is not evidence. There is no development program, no pharmaceutical investment, no path to FDA approval, and no safety data in any species beyond basic rodent studies. The gap between “interesting mouse data” and “effective human treatment” is enormous — most compounds that show promise in rodent depression models fail in human trials. Patients should understand this is a purely research compound with no therapeutic validation of any kind.